Antigenic's Cancer Vaccine Continues to Push it Higher |
 |
 |
| By Jamie Tera | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Wednesday, 03 June 2009 16:44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
On Monday, Antigenics annouced that patients with kidney cancer at intermediate risk of disease recurrence showed about 46 percent lower risk of death when treated with the cancer vaccine, Oncophage. Shares of the company have shot up more than four-fold since its Friday's close of 73 cents.
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares of Antigenics Inc. (Nasdaq:AGEN) rose since the opening bell Wednesday. The stock ended up +$1.12 at $2.54 on above average volume after seeing a day high of $3.34. The biotechnology company is focused on developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.
Today, they added to the sharp gains it had after the company presented interim survival data from a study of Oncophage on Monday. The stock is now trading at a new high for the year. 
Free Phone Trade Alerts
